Company intelligence / Profile preview

Verily

Coppell/Dallas, Texas, United Statesverily.com ↗

Ownership: Private
Development stage: Commercial

Overview

Verily has demonstrated the ability to generate large-scale multimodal datasets for diseases such as Parkinson’s through wearable devices and advanced analytics. Its Study Watch has been validated in longitudinal studies. The company provides commercial solutions for diabetes care optimization and public health surveillance.

Therapeutic areas: OtherEndocrinologyNeurologyInfectious Diseases
Modalities: DeviceDigital health technologyWearable deviceData analytics platform
Industry: Physiological Monitoring

Partnerships

DexcomAlcon/Novartis Eye Care DivisionGSKAmerican Heart AssociationStanford UniversityDuke UniversityCalifornia Health & Longevity InstituteMichael J. Fox Foundation/Radboud University Medical CenterU.S. Centers for Disease Control and Prevention

Beyond the preview

Go deeper on Verily.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verily.

Explore the full profile